News / Stocks
Obsidian Financial’s Morning Market News for Thursday October 20, 2011: eMamba International Corp., Green Mountain Coffee Roasters Inc., Amylin Pharmaceuticals Inc., Eli Lilly and Co., Neoprobe Corporation
OFinancialinc.com, the investor's choice for small-cap alerts, provides stock alerts of the most active small to big cap stocks for early signs of potentially big stock moves. Early timing is critical for catching these potentially explosive stock moves. To receive our FREE "OFC Stock Alert Newsletter" and get more early alerts, please visit our website: OFinancialinc.com.
eMamba International Corp. (OTC: EMBA), an emerging provider of cloud-based business software and after-sales customer services, is pleased to invite our shareholders to participate in a telephone conference call focusing on key recent developments in our sales, operations and financing. The call will also address our goals and plans for the immediate and long-term future. When: Wednesday, October 26th, 2011, 4:15PM EST
To view the full press release for eMamba International Corp. (OTC: EMBA), visit OFinancialinc.com
Other stocks highlighted include:
Green Mountain Coffee Roasters Inc. (NASDAQ: GMCR) outlined its plans for continued growth in Vermont. At present, the company operates from multiple locations in Essex, Waterbury and Williston, Vermont. Green Mountain said yesterday 10/19/11, it is planning for growth in all three communities as well as for new locations in South Burlington. Lawrence Blanford, president and CEO, said, "As we look to support the continued growth in our business, we expect to lease additional office space, build-out new facilities and hire new employees in multiple communities across Vermont. With these expansion plans, we could increase our Vermont employee base by 30% over the next 12 to 18 months."
Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) and Eli Lilly and Co. (NYSE: LLY) said Wednesday 10/19/11, the US. Food and Drug Administration has approved a new use for BYETTA (exenatide) injection. According to the companies, BYETTA is now approved as an add-on therapy to insulin glargine, with or without metformin and/or a thiazolidinedione, along with diet and exercise for adults with type 2 diabetes who are not achieving adequate glycemic control on insulin glargine alone. "This expanded use for BYETTA is important for clinical care, in that it provides a new option for the many patients with type 2 diabetes who are not achieving treatment goals," said John Buse, professor of medicine, director of the Diabetes Care Center and chief of the Division of Endocrinology at the University of North Carolina School of Medicine. In the study supporting the expanded use, patients receiving insulin glargine, with or without metformin and/or thiazolidinedione (TZD), were randomized to receive BYETTA or placebo in addition to aggressive insulin titration. After 30 weeks of treatment, blood sugar level decreased by 1.7 percentage points in patients adding BYETTA, compared with a decrease of 1.0 percentage point in patients treated with insulin glargine alone. Nausea, which was the most common adverse event, occurred in 41 percent of patients treated with BYETTA compared with 8 percent of patients treated with insulin glargine alone.
Neoprobe Corporation (NYSE: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced yesterday 10/19/11, that its New Drug Application (NDA) for Lymphoseek®(tilmanocept) has been accepted for review by the U.S. Food and Drug Administration (FDA). Neoprobe submitted the Lymphoseek NDA on August 10, 2011. Neoprobe seeks U.S. clearance to market Lymphoseek for use in Intraoperative Lymphatic Mapping (ILM), a surgical oncology procedure in which lymph nodes draining the area around a tumor are identified and biopsied to determine if cancer has spread to the lymph nodes. “The acceptance of the Lymphoseek NDA filing marks a critical milestone for the clinical and regulatory development of this agent. Lymphoseek has undergone study in two prospective, well- controlled and designed Phase 3 clinical trials under the direction of nearly 30 investigators in more than 500 patients,” said Rodger A. Brown, Vice President, Regulatory Affairs and Quality Assurance, of Neoprobe. “We look forward to working in collaboration with the FDA to prepare for its pending review of the NDA.”
About OFinancialInc.com:
OFinancialInc.com, a leader in corporate communications and finance, provides investors with a wide-ranging set of financial tools, including original stock market commentary, stock quotes, interactive charts, portfolio watch, live chat and message boards, plus the latest news, press releases, investment opinions, and research reports for all companies highlighted on the site. Visit http://StockPromoters.com for more details. All material herein was prepared by Obsidian Financial Communications, Inc. (OFC) based upon information believed to be reliable. The information contained herein is not guaranteed by OFC to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. OFC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://OFinancialinc.com or mentioned herein. eMamba International Corp. (OTC: EMBA) - OFC has not been compensated for EMBA. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. OFC's affiliates, officers, directors and employees may own shares and intend to buy and sell additional shares of the companies mentioned herein and may profit in the event those shares rise in value. OFC will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. To see OFC's full disclaimer / compensation, please visit our web site: http://ofinancialinc.com/disclaimer
Joe Farrar, CEO, Obsidian Financial Communications, Inc.
OFinancialInc.com
631.675.6932
